Payload ID	PAY0HYAIC
Name	GRM payload C1
Synonyms	GRM payload C1    Click to Show/Hide
Formula	C28H32FNO6
Isosmiles	O=C1C=C2CC[C@H]3[C@@H]4C[C@@H](O[C@H]5C6=CC=C(N)C=C6)[C@@](C(CO)=O)(O5)[C@@]4(C)C[C@H](O)[C@]3(F)[C@@]2(C)C=C1
InChI	InChI=1S/C28H32FNO6/c1-25-10-9-18(32)11-16(25)5-8-19-20-12-23-28(22(34)14-31,26(20,2)13-21(33)27(19,25)29)36-24(35-23)15-3-6-17(30)7-4-15/h3-4,6-7,9-11,19-21,23-24,31,33H,5,8,12-14,30H2,1-2H3/t19-,20-,21-,23+,24+,25-,26-,27-,28+/m0/s1
InChIKey	ACTDQNDKLAACFG-FMIHUGCCSA-N
Pharmaceutical Properties	Molecule Weight		497.563	Polar area		119.08
	Complexity		1160.923654	xlogp Value		2.9637
	Heavy Count		36	Rot Bonds		3
	Hbond acc		7	Hbond Donor		3

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.44 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 34 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.48 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 26 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.51 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.53 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 36 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.54 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 38 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.55 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 19 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.55 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 42 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.6 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.72 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 23 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.72 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.74 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.78 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.79 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.8 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.81 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.82 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.84 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.86 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.92 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.95 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 15 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.03 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 13 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.05 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 29 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.08 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.26 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 19 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.4 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.49 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 44 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.69 ug/mL	High TNF expression (TNF +++)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (TNF)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 20 ug/mL	Negative TNF expression (TNF-)
Method Description	ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.    Click to Show/Hide
In Vitro Model	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia	K562 cells (wt)		CVCL_0004

Ref 1	Impact of dipeptide on ADC physicochemical properties and efficacy identifies Ala-Ala as the optimal dipeptide